P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV)
US10548980B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 13, 2017 |
| Grant date | Feb 4, 2020 |
| Priority date | — |
| Expiry date | Jan 13, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.